McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan and MBHB associate Nicole E. Grimm co-authored an article entitled, “The Intersection of Patent Infringement and Antitrust Liability in Abbreviated New Drug Application Litigation” that appears in the Spring 2014 edition of the Journal of Dispute Resolution as published by the University of Missouri School of Law. A battle has been raging, over the past ten years, regarding the competing interests of patent protection and antitrust prohibitions in the specialized area of law concerned with patented drugs regulated by the Food and Drug Administration (“FDA”). The contestants are the Federal Trade Commission (“FTC”) and parties to Abbreviated New Drug Application (ANDA) litigation, which are a branded drug company and a generic challenger. View the article
